Mouse Anti-GCH1 Recombinant Antibody (4A12) (V2LY-1225-LY895)
Compare
Online Inquiry
Basic Information
| Application | Note |
| ELISA | 1:100-1:1,000 |
| WB | 1:100-1:1,000 |
| IP | 1-2 µg per 100-500 µg of total protein (1 ml of cell lysate) |
| IF(ICC) | 1:50-1:500 |
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
Dopamine biosynthetic process Source: UniProtKB
Negative regulation of blood pressure Source: Ensembl
Neuromuscular process controlling posture Source: MGI
Nitric oxide biosynthetic process Source: UniProtKB
Positive regulation of heart rate Source: Ensembl
Positive regulation of nitric-oxide synthase activity Source: UniProtKB
protein-containing complex assembly Source: Ensembl
Pteridine-containing compound biosynthetic process Source: UniProtKB
Regulation of blood pressure Source: UniProtKB
Regulation of lung blood pressure Source: Ensembl
Regulation of removal of superoxide radicals Source: BHF-UCL
Response to interferon-gamma Source: UniProtKB
Response to lipopolysaccharide Source: UniProtKB
Response to pain Source: UniProtKB
Response to tumor necrosis factor Source: UniProtKB
Tetrahydrobiopterin biosynthetic process Source: UniProtKB
Tetrahydrofolate biosynthetic process Source: InterPro
Vasodilation Source: Ensembl
A disease characterized by malignant hyperphenylalaninemia due to tetrahydrobiopterin deficiency, and defective neurotransmission due to depletion of the neurotransmitters dopamine and serotonin. The principal symptoms include: psychomotor retardation, tonicity disorders, convulsions, drowsiness, irritability, abnormal movements, hyperthermia, hypersalivation, and difficulty swallowing. Some patients may present a phenotype of intermediate severity between severe hyperphenylalaninemia and mild dystonia. In this intermediate phenotype, there is marked motor delay, but no mental retardation and only minimal, if any, hyperphenylalaninemia.
Dystonia, dopa-responsive (DRD):
A form of dystonia that responds to L-DOPA treatment without side effects. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DRD typically presents in childhood with walking problems due to dystonia of the lower limbs and worsening of the dystonia towards the evening. It is characterized by postural and motor disturbances showing marked diurnal fluctuation. Torsion of the trunk is unusual. Symptoms are alleviated after sleep and aggravated by fatigue and exercise.
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon
$30 eGift Card
Submit a review
Loading...
Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols
Alternative Versions
Mouse Anti-GCH1 Recombinant Antibody (4A12) (CAT#: CBMAB-G2609-LY)
Antibody Pairs
GCH1 Matched Antibody Pair (473) (CAT#: APMAB-473LY)
Related Products
Mouse Anti-GCH1 Recombinant Antibody (4A12) (CAT#: CBMAB-G2609-LY)
Mouse Anti-GCH1 Recombinant Antibody (CBLG1-801) (CAT#: V2LY-1225-LY896)
Mouse Anti-GCH1 Recombinant Antibody (CBLG1-056) (CAT#: CBMAB-G0294-LY)
GCH1 Matched Antibody Pair (473) (CAT#: APMAB-473LY)
Mouse Anti-GCH1 Recombinant Antibody (CBLG1-801) (CAT#: CBMAB-G2610-LY)
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
